About the Authors

Violetta Rozani

Affiliation Department of Epidemiology, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Nir Giladi

nirg@tlvmc.gov.il

Affiliations Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Baruch El-Ad

Affiliation Maccabi Healthcare Services, Tel Aviv, Israel

Tanya Gurevich

Affiliations Neurological Institute, Tel Aviv Medical Center, Tel Aviv, Israel, Sagol School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Judith Tsamir

Affiliation Maccabi Healthcare Services, Tel Aviv, Israel

Beatriz Hemo

Affiliation Maccabi Healthcare Services, Tel Aviv, Israel

Chava Peretz

Affiliation Department of Epidemiology, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Competing Interests

Dr. B. El-Ad, Mrs. Judith Tsamir and Mrs. Biatriz Hemo are employed by Maccabi health services. Prof. N. Giladi- serves as a member of the Editorial Board for the Journal of Parkinson's Disease. He serves as consultant to Teva-Lundbeck, IntecPharma, NeuroDerm, Armon Neuromedical Ltd\Dexel, Monfort and Lysosomal Therapeutic Inc. He received payment for lectures at Teva-Lundbeck, Novartis, UCB, Abviee, Shire and Genzyme. Prof. Giladi received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel Science Foundation as well as from Teva NNE program, LTI, and Abviee and CHDI. He owns stock in Lysosomal Therapeutic Ltd. He owns Intellectual Property Rights (Tel-Aviv Medical Center, parkinsonian monitoring by body fixed sensors of motion and behaviour). He has given expert testimony for GSK about impulse control disturbances in PD. He serves on the Advisory Board of Teva-Lundbeck, LTI, Dexel, Abviee, NeuroDerm, Intec Pharma and as the chairman of the DSMB of Pharma2B. He received honoraria from Teva-Lundbeck, Novartis, UCB, Movement Disorders Society, Genzyme, Sheir, Asian Neurorehabilitation Society. He receives royalties from LTI. Dr. B. El-Ad- serves as consultant to Teva and as advisory boards to Shire. He received honoraria for lectures on behalf of Teva, Abbvie, Pfizer and Novartis. Dr. T. Gurevich serves as consultant to Abbvie. She received honoraria (from Abbvie and Novartis) and grants (from National Parkinson ’s disease Foundation). She supports for the participation in scientific meetings from Teva, Medisson, Abbvie, Allergan, Intecpharma, Megapharm, Novartis and Neuroderm. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.

Author Contributions

Conceptualization: VR NG BE TG CP. Data curation: VR JT BH CP. Formal analysis: VR JT BH CP. Funding acquisition: VR. Investigation: VR NG BE TG JT BH CP. Methodology: VR CP. Project administration: VR NG BE CP. Software: VR JT BH CP. Supervision: NG CP. Visualization: VR NG BE TG CP. Writing – original draft: VR. Writing – review & editing: VR NG BE TG CP.